News
Second Genome Appoints Glenn Nedwin, Ph.D., as Chief Executive Officer
July 13, 2016, South San Francisco, CA
Second Genome Secures $42.6 Million in Series B Financing Led by Pfizer Venture Investments and Roche Venture Fund
April 20, 2016, South San Francisco, CA
Second Genome Announces Inflammatory Bowel Disease Research Alliance with the APC Microbiome Institute at University College Cork
April 27, 2015, South San Francisco, CA
Second Genome Advances Lead Microbiome Drug Development Program in Phase I Clinical Trial as a Treatment for Inflammatory Bowel Disease
January 12, 2015, South San Francisco, CA
Second Genome and Mayo Clinic Enter Collaboration to Develop Microbiome Therapeutics in Multiple Diseases
October 7, 2014, South San Francisco, CA
Second Genome Appoints Karim Dabbagh, Ph.D., as Chief Scientific Officer
September 2, 2014, South San Francisco, CA
Second Genome Enters Into Agreement with Pfizer Inc. on Microbiome Research Initiative in Obesity
May 2, 2014, South San Francisco, CA
Second Genome Announces Agreement with Janssen on Microbiome Drug Discovery in Ulcerative Colitis
June 5, 2013, San Bruno, CA